The estimated Net Worth of William A Hagstrom is at least $1.65 Milion dollars as of 9 June 2021. Mr. Hagstrom owns over 5,000 units of Caredx Inc stock worth over $672,595 and over the last 10 years he sold CDNA stock worth over $736,000. In addition, he makes $238,217 as Independent Director at Caredx Inc.
William has made over 6 trades of the Caredx Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of CDNA stock worth $24,750 on 9 June 2021.
The largest trade he's ever made was exercising 15,000 units of Caredx Inc stock on 6 May 2020 worth over $18,300. On average, William trades about 1,875 units every 20 days since 2015. As of 9 June 2021 he still owns at least 23,575 units of Caredx Inc stock.
You can see the complete history of Mr. Hagstrom stock trades at the bottom of the page.
William A. Hagstrom serves as Independent Director of the Company. Since 2014, Mr. Hagstrom has served as the founder and CEO of Octave Bioscience, an early stage molecular diagnostics company focused on neurodegenerative diseases and conditions. Mr. Hagstrom has served on the Board of Directors of Genalyte, Inc. since June 2016, the Board of Directors of Navican Genomics Incorporated since October 2016, and the Board of Directors of CoFactor Genomics, Inc. since April 2018. In 2007, Mr. Hagstrom secured financing for Crescendo Bioscience, a specialty diagnostics company focused on autoimmune and inflammatory diseases managed by rheumatologists. Serving as president and chief executive officer, he led the development of the company’s product pipeline, operations infrastructure and commercial strategy. In 2014, Crescendo Bioscience was acquired by Myriad Genetics as a wholly-owned subsidiary. Before founding Crescendo Bioscience, Mr. Hagstrom was president of Alpha BioPartners, a strategic consulting firm for early stage biotechnology companies. While at Alpha BioPartners, Mr. Hagstrom co-founded Biolytx Pharmaceuticals and Altheus Therapeutics. Mr. Hagstrom also served as interim CEO of Selexys Pharmaceuticals and Inoveon. Prior to this he was Chairman and CEO of UroCor, a specialty diagnostics company focused on urological cancers and complex diseases. Under Mr. Hagstrom’s leadership, the company was an Inc. 500 company from 1992 through 1995, before becoming public in 1996. Previously, Mr. Hagstrom held executive positions at some of the largest multinational healthcare companies in the world, including Becton Dickinson, American Hospital Supply and Baxter International, where he served as vice president of the company’s billion-dollar scientific products division. Mr. Hagstrom has served on a variety of Boards over the last 15 years, including Prometheus Laboratories. Mr. Hagstrom received a B.S. degree in Business Management from Bob Jones University.
As the Independent Director of Caredx Inc, the total compensation of William Hagstrom at Caredx Inc is $238,217. There are 14 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
William Hagstrom is 62, he's been the Independent Director of Caredx Inc since 2015. There are 3 older and 12 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
William's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon oraz Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: